BrainsWay Ltd. (NASDAQ:BWAY) Sees Large Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 80,200 shares, a growth of 27.3% from the January 31st total of 63,000 shares. Based on an average trading volume of 67,400 shares, the short-interest ratio is presently 1.2 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a research note on Monday, December 23rd.

BrainsWay Stock Down 1.5 %

Shares of NASDAQ BWAY traded down $0.15 during midday trading on Thursday, reaching $9.55. 12,862 shares of the stock were exchanged, compared to its average volume of 68,736. The firm has a 50-day simple moving average of $10.21 and a two-hundred day simple moving average of $9.53. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.79. The firm has a market cap of $179.80 million, a price-to-earnings ratio of 95.51 and a beta of 1.29.

Hedge Funds Weigh In On BrainsWay

A number of large investors have recently added to or reduced their stakes in the stock. Valor Management LLC purchased a new stake in BrainsWay during the 4th quarter worth approximately $19,838,000. Phoenix Financial Ltd. boosted its stake in shares of BrainsWay by 100.8% in the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock worth $4,552,000 after acquiring an additional 242,366 shares during the last quarter. ARK Investment Management LLC purchased a new stake in shares of BrainsWay during the fourth quarter worth approximately $1,656,000. MYDA Advisors LLC raised its stake in BrainsWay by 100.2% in the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock valued at $1,133,000 after purchasing an additional 60,100 shares during the last quarter. Finally, Zuckerman Investment Group LLC lifted its holdings in BrainsWay by 346.4% in the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock valued at $667,000 after purchasing an additional 51,991 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.